Scrip Calculation Price for December 2013

RNS Number : 6813T

The MedicX Fund Limited

21 November 2013

 



For immediate release

21 November 2013

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

Scrip Calculation Price for December 2013 Dividend in relation to the Scrip Dividend Scheme

On 17 May 2010 the Board of MedicX Fund Limited announced an opportunity for qualifying Shareholders to receive relevant dividends in new ordinary shares instead of in cash (the "Scheme").

In relation to the dividend for the period 1 July 2013 to 30 September 2013 payable on 31 December 2013 (the "December 2013 Dividend"), the price of a new ordinary share in relation to the Scrip Dividend Scheme (the "Scrip Calculation Price") has been set at 80.55 pence. This is the average of the closing middle market quotations for the Company's ordinary shares for the five consecutive business days commencing on the ex-dividend date of 13 November 2013.

In order to be valid, Mandate forms must be received by the Company's registrars, Capita Asset Services, (or CREST instructions entered) by no later than 5.00 p.m. on  6 December 2013 (the "Mandate Delivery Deadline") in order for elections under the Scrip Dividend Scheme to be effective in relation to the December 2013 Dividend. The Company mailed, on 19 November 2013, personalised Mandate Forms to Shareholders new on the Register since 16 August 2013 and before 15 November (the "Record Date").  Other Shareholders can use their Mandate Forms issued for previous scrip dividends offered, or obtain Mandate Forms from Capita Asset Services.

Mandate Forms remain valid for all Relevant Dividends where a Scrip Dividend Alternative is offered, until cancelled. Therefore, Shareholders who have previously completed a Mandate Form but no longer wish to receive a Scrip Dividend should write to Capita Registrars (at the address on page 5 of the Chairman's letter) by no later than 5.00 p.m. on the Mandate Delivery Deadline for the Relevant Dividend to inform them that they wish to revoke the election and receive a cash dividend. 

Shareholders who do not wish to receive a Scrip Dividend Alternative and have not previously completed a Mandate Form need take no further action and will receive a cash dividend in respect of the December 2013 Dividend in the usual way. The payment date in respect of the December 2013 Dividend is 31 December 2013. 

Shareholders who have any questions regarding the Scrip Dividend Scheme should contact the Capita Asset Services helpline on 0871 664 0300*.

*Calls made to this number are charged at 10 pence per minute plus network charges. Lines are open 8.30 a.m. to 5.30 p.m. (London time) Monday to Friday (except Bank Holidays).

End

For further information please contact:

MedicX Group                                                                [phone]

Keith Maddin, Chairman

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

Canaccord Genuity Limited                                                [phone]

Andrew Zychowski/Helen Goldsmith

Buchanan Communications                                             [phone]

Charles Ryland/Sophie McNulty

MedicX Fund Limited                                                      [phone]

David Staples, Chairman

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 122 properties.

The Investment Adviser to the Company is MedicX Adviser Ltd, which is authorised and regulated by the Financial Conduct Authority and is a subsidiary of the MedicX Group. The MedicX Group is a specialist investor, developer and manager of healthcare properties with 31 people operating across the UK.  

The Company's website address is www.medicxfund.com.  Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

END

 

 

MSCBBBRTMBJTBAJ